Von Willebrand-Related Test Abnormalities
Low value for von Willebrand factor (vWF) and/or ristocetin cofactor (RCoF) or values in the low end of these normal ranges with a history of mild bleeding affecting males and females in the family suggest von Willebrand disease (vWD).
vWD could be type 1, 2A, 2B, 2M, 2N, or 3.
A person with blood type O who does not have vWD, since persons with blood type O have a mean vWF of only about 75% of normal.
Suggested Additional Lab Testing
RCoF, vWF, and factor VIII level (factor VIII level often decreases along with the other 2).
In type 1 vWD, RCoF and vWF are suppressed approximately equally and mildly abnormal.
In type 2, vWF is typically greater than or equal to 15% greater than RCoF, and the values for both are in the 20% range or lower.
In type 3, both of these values approximate 0.
Fibrinogen is an important measurement, because it is an acute phase reactant.
Fibrinogen elevation suggests that RCoF and vWF levels do not represent the patient's true baseline values and that a repeat test at a later time is necessary.
Obtain blood type: mean value for vWF varies with blood type.
VWF multimer analysis by agarose gel electrophoresis and Western blotting is useful when there is a high likelihood of non-type 1 vWD.
Desmopressin (DDAVP) stimulation test (except if the patient has type 2B or platelet type vWD) may be useful to determine if DDAVP can be used clinically to treat vWD.
In the test, samples for RCoF and vWF are taken before DDAVP administration and then again 60 minutes after completion of a 30-minute infusion of DDAVP.
Copyright © 2017, 2013 Decision Support in Medicine, LLC. All rights reserved.
No sponsor or advertiser has participated in, approved or paid for the content provided by Decision Support in Medicine LLC. The Licensed Content is the property of and copyrighted by DSM.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- A Ketogenic Diet as an Adjunct to Cancer Treatment
- Patient-Reported Outcomes in Oncology Expected to Make Regulatory Waves
- Blinatumomab-Ponatinib Salvage Therapy in B-Cell Acute Lymphoblastic Leukemia: Case Report of Benefit
- FDA Provides Update on Breast Implant-Associated Anaplastic Large Cell Lymphoma
- Metastatic Prostate Cancer Responds to Novel Radiation Therapy
- Nivolumab-Ipilimumab Survival Benefit in Advanced RCC Confirmed
- Two-Drug Combination Superior to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma
- Adding Chemotherapy to Radiation Post-Radical Cystectomy Improves Survival in Urothelial Carcinoma
- Radiation, Chemotherapy Not Beneficial in Localized Upper Tract Urothelial Carcinoma
- Radical Cystectomy Superior to Trimodal Therapy for Muscle-Invasive Bladder Cancer